Previous 10 | Next 10 |
PARIS and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibi...
Nanobiotix S.A (NBTX) Q2 2022 Earnings Conference Call September 29, 2022, 08:00 AM ET Company Participants Laurent Levy - Co-Founder, CEO Bart Van Rhijn - CFO Kate McNeil - IR Conference Call Participants Jon Miller - Evercore Suzanne van Voorthu...
Nanobiotix press release ( NASDAQ: NBTX ): 1H GAAP EPS of -€0.76. Revenue of €1.33M (+0.8% Y/Y) beats by €0.11M . Cash and Cash Equivalents: Cash and cash equivalents as of June 30, 2022, were €63.0 million, compared to €83...
Pivotal Phase 3 study, NANORAY-312, actively enrolling elderly, LA-HNSCC patients ineligible for cisplatin across ~50 sites as LianBio enrolls first patient and continues to ramp up site activation in Asia and Nanobiotix adds European sites, and begins recruitment in the US Re...
Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on September 29, 2022 Regulatory News: NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology com...
Recommended phase 2 dose established at 33% of gross tumor volume in all three cohorts from the complete escalation part of Study 1100 Updated clinical data from Study 1100 expected in Q4 2022 Submission of protocol to United States Food and Drug Administration for P...
French biotech Nanobiotix ( NASDAQ: NBTX ) on Monday said it had reached an agreement in principle to restructure €30.7M in outstanding debt obligations related to its 2018 loan agreement with the European Investment Bank. NBTX said the debt restructuring was done t...
Debt restructuring supports corporate priorities by realigning debt obligations with expected development and commercialization timelines Execution of the definitive amendment is expected in Q4 2022 after finalization of legal documentation Regulatory News: ...
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) Regulatory News: Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Eur...
Regional activation for Nanobiotix pivotal Phase 3 trial in head and neck cancer proceeds as planned with first patient enrolled in Asia by partner LianBio The collaboration continues to build momentum behind LianBio’s leadership in Asia while Nanobiotix remains focus...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...